A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT03439293 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Ixazomib
DRUG: Daratumumab
DRUG: Dexamethasone

Sponsor

Takeda